Skip to content
Bored Studies
RecruitingPhase 2

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Merck Sharp & Dohme LLC · NCT07033494

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
340
US sites recruiting
35
Study start
July 16, 2025
Record last updated
October 20, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.

The goals of the study are to learn

  • If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
  • About the safety of MK-2214 and if people tolerate it

Being studied: MK-2214; Placebo

Conditions: Early Alzheimer's Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

  • Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
  • Has a designated study partner who can fulfill the requirements of this study
  • If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

  • Has a known history of stroke or cerebrovascular disease
  • Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
  • Has structural brain disease
  • Has a history of seizures or epilepsy within 5 years before screening
  • Has any other major central nervous system trauma, or infections that affect brain function
  • Has major medical illness or unstable medical condition within 3 months before screening
  • Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
  • Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study
  • Has a bleeding disorder that is not under adequate control
  • Has a history of malignancy occurring within 5 years of screening
  • Has a risk factor for corrected QT interval (QTc) prolongation
  • Has liver disease
  • Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan
  • Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision

Recruiting US locations

  • Irvine Clinical Research ( Site 1041)

    Irvine, CA 92614

    Site contact: Study Coordinator · 949-753-1663

  • Healthy Brain Clinic ( Site 1005)

    Long Beach, CA 90804

    Site contact: Study Coordinator · 562-606-5999

  • Inglewood Clinical ( Site 1062)

    Los Angeles, CA 90056

    Site contact: Study Coordinator · 949-265-1612

  • Anderson Clinical Research ( Site 1024)

    Redlands, CA 92374

    Site contact: Study Coordinator · 909-792-9007

  • UCSF Memory and Aging Center ( Site 1031)

    San Francisco, CA 94158

    Site contact: Study Coordinator · 415-353-3585

  • Syrentis Clinical Research ( Site 1001)

    Santa Ana, CA 92705

    Site contact: Study Coordinator · 714-542-3008

  • Yale University, Alzheimer's Disease Research Unit ( Site 1059)

    New Haven, CT 06510

    Site contact: Study Coordinator · 203-764-8100

  • JEM Research Institute ( Site 1046)

    Atlantis, FL 33462

    Site contact: Study Coordinator · 561-968-2933

  • Neuropsychiatric Research Center of Southwest Florida ( Site 1003)

    Fort Myers, FL 33912

    Site contact: Study Coordinator · 239-939-7777

  • K2 Medical Research ( Site 1047)

    Maitland, FL 32750

    Site contact: Study Coordinator · 407-500-5252

  • ClinCloud LLC ( Site 1039)

    Melbourne, FL 32940

    Site contact: Study Coordinator · 407-680-0534

  • Indago Research and Health Center Inc ( Site 1044)

    Miami Lakes, FL 33016

    Site contact: Study Coordinator · 305-825-6588

  • Aqualane Clinical Research ( Site 1035)

    Naples, FL 34105

    Site contact: Study Coordinator · 239-529-6780

  • Suncoast Clinical Research ( Site 1007)

    New Port Richey, FL 34652

    Site contact: Study Coordinator · 727-849-4131

  • Renstar Medical Research ( Site 1012)

    Ocala, FL 34471

    Site contact: Study Coordinator · 352-629-5800

  • Charter Research - Orlando ( Site 1051)

    Orlando, FL 32803

    Site contact: Study Coordinator · 407-337-3000

  • Axiom Brain Health ( Site 1029)

    Tampa, FL 33609

    Site contact: Study Coordinator · 813-353-9613

  • K2 Medical Research ( Site 1020)

    Tampa, FL 33634

    Site contact: Study Coordinator · 813-800-5252

  • Charter Research - Lady Lake ( Site 1019)

    The Villages, FL 32162

    Site contact: Study Coordinator · 352-775-1000

  • Conquest Research LLC ( Site 1053)

    Winter Park, FL 32789

    Site contact: Study Coordinator · 407-916-0060

  • CenExel iResearch, LLC ( Site 1015)

    Decatur, GA 30030

    Site contact: Study Coordinator · 404-537-1281

  • Alexian Brothers Medical Center-Neurosciences ( Site 1017)

    Elk Grove Village, IL 60007

    Site contact: Study Coordinator · 847-593-8553

  • Boston Center for Memory ( Site 1008)

    Newton, MA 02459

    Site contact: Study Coordinator · 617-699-6927

  • CenExel- AMRI ( Site 1018)

    Marlton, NJ 08053

    Site contact: Study Coordinator · 732-341-9500

  • The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064)

    Ridgewood, NJ 07450

    Site contact: Study Coordinator · 201-850-4622

  • The Cognitive and Research Center of NJ ( Site 1057)

    Springfield, NJ 07081

    Site contact: Study Coordinator · 973-850-4622

  • Alzheimer Disease Research Center (ADRC) ( Site 1000)

    Albany, NY 12208

    Site contact: Study Coordinator · 518-426-0575

  • Mid Hudson Medical Research ( Site 1050)

    New Windsor, NY 12553

    Site contact: Study Coordinator · 845-674-9398

  • Basil Clinical ( Site 1065)

    Queens, NY 11413

    Site contact: Study Coordinator · 917-672-3275

  • AMC Research, LLC ( Site 1006)

    Matthews, NC 28105

    Site contact: Study Coordinator · 704-364-4000

  • Insight Clinical Trials ( Site 1011)

    Independence, OH 44131

    Site contact: Study Coordinator · 216-245-6556

  • Neuro-Behavioral Clinical Research ( Site 1028)

    North Canton, OH 44720

    Site contact: Study Coordinator · 330-493-1118

  • Flourish Research ( Site 1048)

    Plymouth Meeting, PA 19462

    Site contact: Study Coordinator · 610-277-8073

  • Gadolin Research ( Site 1032)

    Beaumont, TX 77702

    Site contact: Study Coordinator · 409-331-6040

  • Horizon Clinical Research Center - Houston ( Site 1026)

    Cypress, TX 77429

    Site contact: Study Coordinator · 949-491-0710

Study contacts (from the official record)

  • Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
All neurology studies in California →
A Clinical Study of MK-2214 in People With Early Alzheimer's… (NCT07033494) | Bored Studies